2020 Guide to Patient Support Services

Bristol-Myers Squibb

Through its Access Support program, Bristol-Myers Squibb (BMS) offers a variety of oncology support options for patients receiving outpatient treatment in the United States and Puerto Rico.

The BMS Access Support program offers a variety of oncology support options for eligible patients who are unable to afford their medications. These may include reviewing patient insurance coverage for BMS medications, the BMS Oncology Co-Pay Assistance Program, navigating prior authorization and claims appeals if coverage is denied, or referring the patient to other financial assistance options for the uninsured or underinsured.

The Table lists the oncology and oncology supportive drugs that are included in the BMS Access Support program. Oral drugs may be shipped to the provider or patient.

The BMS Access Support program can refer you to independent charitable foundations that may be able to provide financial support, including the BMS Patient Assistance Foundation, a charitable organization that provides medicine, free of charge, to eligible, uninsured patients who have an established financial hardship.

The BMS Patient Assistance Foundation accepts the Access Support application. For more information, visit BMSPAF.org.

ELIGIBILITY

BMS Oncology Co-Pay Assistance Program

This program is designed for commercially insured patients who need financial assistance with out-of-pocket deductibles, copays, or coinsurance, as indicated in the Explanation of Benefits form.

The program covers select BMS oncology drugs, including Empliciti (elotuzumab), Opdivo (nivolumab), and Yervoy (ipilimumab).

Eligible patients pay the first $25 of their copay for an infusion. BMS will cover the remainder of their copay, up to $25,000 annually per medication, or up to $50,000 annually for a 2-drug combination.

Patients whose infusions are covered by a federal healthcare program, such as Medicare, Medicaid, or TRICARE, are not eligible for this program.

For patients with no medical insurance, BMS Access Support can make a referral to independent charitable foundations, including the BMS Patient Assistance Foundation, which may be able to provide financial support for BMS medications.

BMS Patient Assistance Foundation

Eligible patients may qualify to receive medications free of charge for up to 1 year. To be eligible, patients:

  • Must be receiving outpatient treatment in the United States, Puerto Rico, or the US Virgin Islands by a US-licensed healthcare provider
  • Must meet the income limits for the requested medication and other insurance criteria; the annual income must be ≤300% of the federal poverty level
  • May also be eligible if they are uninsured or have been denied coverage for the requested medication.

For more information on this ­program, visit BMSPAF.org, or call 800-736-0003.

Yervoy with You

Patients prescribed Yervoy can receive ongoing support during their treatment through the Yervoy with You program. Click here for more information on this program, or call 855-493-7869.

APPLICATION & ENROLLMENT

BMS Oncology Co-Pay Assistance Program

To enroll in the BMS Oncology Co-Pay Assistance Program, the enrollment form must be completed online or faxed to 888-776-2370. Enrollment forms are available online.

The BMS Access Support program will determine the patient’s eligibility, including verification of insurance coverage and benefits amount. An explanation of benefits must be submitted within 180 days of receiving each dose. For more information on Sprycel Assist or the Sprycel One Card, visit Sprycel.com/sprycel-assist or call 855-777-9235.

BMS Patient Assistance Foundation

An application to be filled out by the patient and healthcare provider is required to enroll in the BMS Patient Assistance Foundation. Proof of income should be submitted with the application, and returned to the foundation by fax to 800-736-1611.

The enrollment form is available at BMSPAF.org. Enrollment is valid for 1 year; re-enrollment every year is required to continue in the program. For more information on this program, call 800-736-0003.

TABLE BMS ONCOLOGY DRUGS

Drugs
Indications
Patient support programs

Drug
Droxia (hydroxyurea)
Indications
Melanoma; chronic myeloid leukemia; ovarian cancer; squamous-cell head and neck cancer (primary)
Patient support program
Good Days
877-968-7233

Drug
Empliciti (elotuzumab)
Indications
Multiple myeloma, in combination with lenalidomide and dexamethasone
Patient support programs

Drug
Opdivo (nivolumab)
Indications
Patient support programs

Drug
Sprycel (dasatinib)
Indications
Ph+ acute lymphoblastic leukemia; newly diagnosed Ph+ chronic myeloid leukemia; chronic-, accelerated-, or myeloid or lymphoid blast-phase Ph+ chronic myeloid leukemia resistant or intolerant to previous therapy
Patient support programs

Drug
Yervoy (ipilimumab)
Indications
Treatment of unresectable or metastatic melanoma in patients ≥12 years; adjuvant treatment of patients with cutaneous melanoma and involvement of regional lymph nodes >1 mm after complete resection, including total lymphadenectomy; first-line treatment of intermediate- or poor-risk advanced renal-cell carcinoma, in combination with nivolumab; treatment of patients ≥12 years with MSI-H or dMMR metastatic colorectal cancer progressing after fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab
Patient support programs

dMMR indicates mismatch repair deficient; HSCT, hematopoietic stem-cell transplantation; MSI-H, microsatellite instability-high; NSCLC, non–small-cell lung cancer; Ph+, Philadelphia chromosome–positive.

Opdivo (nivolumab) Indications

Unresectable or metastatic melanoma with BRAF V600 wild-type; metastatic NSCLC; advanced renal-cell carcinoma; classical Hodgkin lymphoma that relapsed or progressed after autologous HSCT; recurrent or metastatic squamous-cell head and neck cancer; locally advanced or metastatic urothelial carcinoma that progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy; patients ≥12 years with MSI-H or dMMR metastatic colorectal cancer that progressed after a regimen of fluoropyrimidine, oxaliplatin, and irinotecan; hepatocellular carcinoma after sorafenib therapy; metastatic small-cell lung cancer that progressed after platinum-based chemotherapy and ≥1 lines of therapy; treatment of patients ≥12 years with MSI-H or dMMR metastatic colorectal cancer progressing after fluoropyrimidine, oxaliplatin, and irinotecan, in combination with ipilimumab

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: